ArticleBMC cancer2025
Clinicopathologic and prognosis of 30 patients with FH-deficient renal cell carcinoma: a single-center retrospective study.
Article in BMC cancer, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- A Multimodal, Multitask Prediction Framework for Diagnosis and Prognosis of Clear Cell Renal Cell Carcinoma.Journal of imaging informatics in medicine · 2026Article
- Pathologic Complete Response After Preoperative Ipilimumab and Nivolumab in an HLRCC Patient with Stage III Renal Cell Carcinoma.Journal of kidney cancer and VHL · 2026Article
- Targeting metabolic and epigenetic reprogramming in metastatic fumarate hydratase-deficient renal cell carcinoma.Clinical & experimental metastasis · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors.
Funding
Abstract
backgroundFH-Deficient Renal Cell Carcinoma (FH-RCC) is a rare, aggressive cancer with poor prognosis and treatment challenges. Immunohistochemical (IHC), including PD-1, PD-L1, PD-L2, and CTLA-4, play a key role in survival outcomes and therapeutic decisions, highlighting the need to evaluate their significance in FH-RCC.
methodsThe expression of IHC including PD-1, PD-L1, PD-L2 and CTLA-4 in tumor cells was evaluated. The clinicopathological and therapeutic information of 30 patients with FHRCC was retrospectively collected and correlation analysis and Kaplan-Meier analysis were performed.
resultsIn a cohort of 30 patients with FHRCC, the majority of tumors exhibited a simple papillary structure. PD-1 positive expression was observed in 43.3% (13/30) of the patients, PD-L1 in 53.3% (16/30), PD-L2 in 20.0% (6/30), and CTLA-4 in 90%. CK-7 showed positive expression in 23.3% of the patients. Notably, PD-L1 positivity was associated with a higher frequency of simple papillary structures and better outcomes in patients receiving TKI monotherapy. Conversely, patients who underwent radical surgery, exhibited negative CK-7 expression, had positive PD-1 expression, and negative PD-L2 expression, demonstrated shorter disease-free survival (DFS). Additionally, those who underwent radical surgery and were PD-L2 negative had worse cancer-specific survival (CSS).
conclusionFH-RCC is highly aggressive and has a poor prognosis, and clinical and pathologic parameters such as IHC expression including PD-1, PD-L1, PD-L2 and CTLA-4 have a predictive value in prognosis and treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.